Literature DB >> 9365202

Aromatase in the normal breast and breast cancer.

A Brodie1, Q Lu, J Nakamura.   

Abstract

Adipose tissue and muscle constitute the larger proportion of body mass, and therefore aromatization in these tissues is the major source of circulating estrogens in postmenopausal women. Although plasma estrogen concentrations are very low, levels in breast cancers from postmenopausal patients are reported to be 10-fold higher than in plasma and normal tissue. Whereas studies on aromatase activity in the tumor suggest that estrogen may be produced locally, the significance of this contribution has been questioned. Using immunocytochemistry (ICC) to an anti-aromatase antibody, a relatively strong immunoreaction was detected in tumor epithelial cells as well as in the terminal ductal lobular units (TDLUs) of the normal breast. Aromatase expression was detected in the cytoplasm of tumor epithelial cells and the surrounding stromal cells of over 50% of tumors in a series of 19 breast cancers. In situ hybridization (ISH) to aromatase mRNA confirmed the immunocytochemical result that the epithelial cells are the primary site of estrogen synthesis in the breast and breast cancers. In the 10 tumors which showed immunoreaction to aromatase, the average aromatase activity measured in cryosections was 286.5 +/- 18.6 fmol estrogen/mg protein/h (SE), whereas in nine tumors with weak aromatase immunoreaction, the enzyme activity was 154.7 +/- 19.3 fmol estrogen/mg protein/h (P < 0.05) (SE). The functional significance of tumor aromatase and locally produced estrogens on the growth of tumors was suggested by the correlation between aromatase activity and proliferating cell nuclear antigen (PCNA), a marker of cell proliferation (P < 0.005). Although intratumoral aromatase activity did not correlate with steroid receptors significantly, there was a trend for estrogen receptor (ER)-positive tumors to express aromatase. In addition, proliferation ([3H]-thymidine incorporation into DNA) during histoculture, was increased by both estradiol and testosterone in tumors with high aromatase activity. Our results suggest that some tumors synthesize sufficient estrogen to stimulate their proliferation. It may thus be important to inhibit tumor aromatase as well as to reduce circulating levels of estrogen for effective breast cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365202

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  23 in total

Review 1.  Estrogen metabolism as a regulator of estrogen action in the mammary gland.

Authors:  M Miettinen; V Isomaa; H Peltoketo; D Ghosh; P Vihko
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

2.  Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.

Authors:  Syreeta L Tilghman; Ian Townley; Qiu Zhong; Patrick P Carriere; Jin Zou; Shawn D Llopis; Lynez C Preyan; Christopher C Williams; Elena Skripnikova; Melyssa R Bratton; Qiang Zhang; Guangdi Wang
Journal:  Mol Cell Proteomics       Date:  2013-05-23       Impact factor: 5.911

Review 3.  Impact of obesity on development and progression of mammary tumors in preclinical models of breast cancer.

Authors:  Margot P Cleary
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-12       Impact factor: 2.673

4.  The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer.

Authors:  Nadiyah Kazmi; Diana C Márquez-Garbán; Lilia Aivazyan; Nalo Hamilton; Edward B Garon; Lee Goodglick; Richard J Pietras
Journal:  Lung Cancer Manag       Date:  2012-12

5.  Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer.

Authors:  Edgar S Díaz-Cruz; Yasuro Sugimoto; G Ian Gallicano; Robert W Brueggemeier; Priscilla A Furth
Journal:  Cancer Res       Date:  2011-08-15       Impact factor: 12.701

6.  The Role of Androgens in Normal and Malignant Breast Tissue.

Authors:  Katharina Tiefenbacher; Günter Daxenbichler
Journal:  Breast Care (Basel)       Date:  2008-10-16       Impact factor: 2.860

7.  Biochanin A inhibits breast cancer tumor growth in a murine xenograft model.

Authors:  Young Jin Moon; Beom Soo Shin; Guohua An; Marilyn E Morris
Journal:  Pharm Res       Date:  2008-05-03       Impact factor: 4.200

8.  Arsenic-induced cancer cell phenotype in human breast epithelia is estrogen receptor-independent but involves aromatase activation.

Authors:  Yuanyuan Xu; Erik J Tokar; Michael P Waalkes
Journal:  Arch Toxicol       Date:  2013-09-26       Impact factor: 5.153

9.  Steroid Hormone Receptors as Potential Mediators of the Clinical Effects of Dutasteride: A Prospective, Randomized, Double-Blind Study.

Authors:  João C C Alonso; Leonardo O Reis; Patrick V Garcia; Ubirajara Ferreira; Wagner E Matheus; Fabiano A Simões; Ronald F Rejowski; Maria Isabel C Alonso-Vale; Wagner J Fávaro
Journal:  Am J Mens Health       Date:  2016-07-08

10.  CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma.

Authors:  Mostafizur Rahman; Sigurd F Lax; Carrie H Sutter; Quynh T Tran; Gaylene L Stevens; Gary L Emmert; Jose Russo; Richard J Santen; Thomas R Sutter
Journal:  Drug Metab Dispos       Date:  2008-02-06       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.